Medivate Partners’ most common sector for investment islife science (100%). The Firm’s most common investment types include growth capital (67%) and buyout (lbo, mbo, mbi) (34%). In total, Medivate Partners has invested in 2 US states and 2 different countries.
Sign-up to view Medivate Partners’ full profile and discover more small private equity firm investors just like it.
15F, Kwangil Plaza, 331,Gangnam-daero, Seocho-gu,
Seoul,
06627
South Korea
+82-2-536-0705
www.medivatepartners.com
info@medivatepartners.com
| Status | Dates | Company | Description | |
|---|---|---|---|---|
| Investment | Exit | |||
| Current | 2016-03-21 | - |
SillaJen Biotherapeutics
Life Science Busan, South Korea www.sillajen.com |
SillaJen Biotherapeutics is a specializing in the translational and clinical development of complex biologics. The SillaJen translational research, assay, and clinical research teams offer an array of services in a quality systems environment to bring investigational products from bench to bedside. Located on the campus of Pusan National University, the company is comprised of dedicated in-house teams that collaborate closely with a network of local and USA-based world-class scientists and physicians. |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
